Premium
CD56‐expression in bone marrow or other relevant tissue samples related to histopathological diagnosis and clinical outcome in children
Author(s) -
Toft Birgitte Groenkaer,
Ryder Lars Peter,
Andersen Mette Klarskov,
Lausen Birgitte Frederiksen,
Petersen Bodil Laub
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a637-c
Subject(s) - medicine , bone marrow , lymphoma , leukemia , myeloid sarcoma , acute leukemia , pathology , myeloid leukemia , myeloid , sarcoma , gastroenterology
In normal bone marrow CD56‐expression is low, but in acute leukemia or lymphoma in adults a marked increase in CD56‐expression is associated with a worse clinical outcome. In children, however, it is unclear whether a high CD56‐expression relates to the histopathological diagnosis and prognosis. In a five‐year period (2000‐05) we retrospectively assessed medical files of children below 15 years of age. As established by flowcytometry, bone marrow or other relevant tissue samples with a percentage of CD56+ cells higher than 10% were selected. Ten patients (age 5.1 ± 1.2 yr; mean ± SEM) were included and in most patients CD56+ analysis was performed at the time of diagnosis. Six patients had acute myeloid leukemia (AML) (66 ± 11% cells expressing CD56) and the remaining four patients were with cutaneous lymphoma (20%), myeloid sarcoma in pleura (40%), juvenile myelomonocytoid leukemia (27%) or large cell anaplastic T‐cell lymphoma (13%), respectively. Two patients with AML and the patient with myeloid sarcoma in pleura died 11 ± 3 months after the diagnosis was established and the %CD56+ cells was 66 ± 13 as compared to 43 ± 12 in the remaining seven children who are still alive (follow‐up time 28 ± 11 months). In this group one patient relapsed during treatment. Our cases with a high expression of CD56+ cells relates to a wide range of diagnosis. As in adults the data suggests that in children the expression of CD56 in acute leukemia is associated with a bad outcome.